The information contained herein is provided for educational purposes
only and is not intended to constitute medical advice or replace discussions with a Healthcare
Professional.All decisions regarding patient care must be made with a Healthcare Professional, considering
the unique characteristics of the patient.
While every effort is made to update the information regularly and
to offer the most current, correct and clearly expressed information possible, Pfizer cannot be held
responsible for any inaccuracy, errors, omissions or misinterpretations.
Pfizer, its officers and/or its employees do not accept or take any
responsibility whatsoever for any loss, whether direct, indirect or consequential, which may arise from
reliance on information contained on these pages and actions resulting therefrom.Any liability that would or
could arise as a result of the contents of these pages is hereby excluded to the fullest extent allowed by
law.
No warranty is given that any files, downloads or applications
available via this web site are free of viruses which have the ability to corrupt your system.
Any and all information is subject to change without notice.
The information provided in this site is intended only for
appropriate Healthcare Professionals residing in SouthAfrica.
WEBINAR SESSION TIME
CDK 4/6 inhibitors:
Addressing
CDK 4/6 inhibitors in HR+ HER2-
ABC Management
CDK 4/6 inhibitors in HR+ HER2-
ABC Management
Navigation of NSCLC
ALK
mutated lung cancer management
mutated lung cancer management
Therapeutic
sequencing in
mRCC: Clinical Characteristics
driving Treatment Choice
mRCC: Clinical Characteristics
driving Treatment Choice
SPEAKERS
CDK 4/6 inhibitors: Addressing CDK 4/6 inhibitors in HR+ HER2- ABC Management
Navigation of NSCLC ALK mutated lung cancer management
Therapeutic sequencing in mRCC: Clinical Characteristics driving Treatment Choice